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It is generally accepted that the external
application of hydrocortisone is highly beneficial
in the treatment of various chronic inflammatory
and pruritic dermatoses, especially of atopic
dermatitis and lichen chronicus simplex (12, 14).
Since the topical use of adrenal corticosteroids
was introduced (Sulzberger and Witten 12), two
questions have arisen: 1) the question of the
possibility of their percutaneous absorption, and
2) that of a risk of undesirable side effects re-
sulting from prolonged usage, comparable with
the effects at times produced by systemic ad-
ministration of these compounds.
Regarding the first question there is experi-
mental evidence that some percutaneous ab-
sorption of corticosteroids may occur following
their topical application. In particular, Malkin-
son and Ferguson (5, 6) detected radioactivity
in the urine following topical application of
hydrocortisone-4-C14 and cortisone-4-C'4 acetate.
Fnder the conditions chosen, the peak of ex-
cretion of both compounds occurred at 48 hours
and was followed by the excretion of smaller
amounts for the next six days. Less than 1 per
cent of the hydrocortisone-4-C'4 applied was
excreted in the urine over a period of six days.
Scott and Kalz (5) demonstrated the presence
of C'4 labelled hydrocortisone inside the skin
after external application. By means of auto-
radiographs the compound was detected in the
epidermis, from where—upon transitory con-
centration in the basal cell layer—it assumedly
moved into the cutis.
A number of investigations were reported in
which laboratory tests were employed to explore
the question of systemic effects of external
corticosteroid application. Danto and Maddin
(1) did not observe any change in the number of
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circulating eosinophiles after the topical applica-
tions of cortisone. Similarly, Smith (9) found no
significant change in the circulating eosinophile
count following the application of 150 mg of
hydrocortisone acetate to normal or clinically
inflamed skin. In a similar investigation this
author failed to note any changes in the urinary
excretion of I 7-ketosteroids and 17-hydroxy-
corticosteroids (10). Witten et al. (19) studied
the blood and urinary levels of 17,21 dihydroxy-
20-ketosteroids in response to external applica-
tion of hydrocortisone for periods of three days
without finding significant changes.
Gcmzell et al. (3) observed a reduction in the
number of circulating eosinophiles and an in-
crease in the 17-hydroxycorticosteroid blood
levels following the inunction of 200 mg of
hydrocortisone incorporated in various vehicles—
but both these changes were of low magnitude.
Tschan and Adoni (18) reported a decline of the
circulating eosinophile count following the
application of 2 ounces of an ointment containing
0.5 per cent prednisolone. This reduction was
observed only when the count was above 100
prior to the inunction—and was significant in
only 3 out of the 9 patients investigated.
All of these tests were carried on for only
short periods of time (i.e. for approximately one
to three days); the amounts of steroid employed
were relatively small; and the skin areas con-
tacted were in many instances unbroken and of
minor extent.
It is for these reasons that the present assays
were undertaken, in an endeavour to find out
whether or not relatively large amounts of
hydrocortisone applied to extensive areas of
damaged skin may upon prolonged usage induce
systemic effects and/or undesirable side effects,
as would be detectable by close clinical observa-
tion and conventional laboratory tests.
METHOD
Procedure, Materials, Subjects
Ten female and nine male patients were
subjected to the study. Their age varied from 5
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to 60 years. Fifteen suffered from atopie (icr-
matitis, one from atopie dermatitis combined
with iehthyosis and three from lichen simplex
chronicus.
Applications were performed twice daily of 2l/
per cent hydroeortisone acetate incorporated in a
base containing lanolin, light mineral oil and
white petrolatum*. The total amount of hydro-
cortisone employed per patient ranged from
8,750 mg to 95,000 mg. The duration of treat-
ment ranged from three to twenty months.
Eighteen of the patients had never previously
received a corticosteroid systemically. Only one
patient had taken prednisolone orally for a
short period of time three months prior to the
study.
Every patient was seen at regular intervals—
not exceeding a two weeks' period.
The patients were carefully observed for
clinical complications such as hypertrichosis,
secondary infections, edema, blood pressure
elevation, increase in weight, gastrointestinal
disorders, or moon face.
Concommitantly the following laboratory tests
were performed at intervals:
1. a. circulating eosinophile count (normal:
50—500 per mm3)
b. eosinophile differential count (normal:
1%-5%)
2. lymphocyte differential count (normal:
20%—40%)
3. monocyte differential count (normal: 2%—
8%)
4. urinary 17-kctostcroid excretion (normal:
females: 5—14 mg./24h; males: 8—23 mg./
24h)
5. blood glucose contents (normal: 60—100
mg.%)
6. serum sodium contents (normal: 300—330
mg.%; 130—143 mEq/L)
7. serum chlorides contents (normal: 560—620
mg.%; 95-105 mEq/L)
8. serum calcium contents (normal: 9.6—11
mg.%; 4.8—5.5 mEq/L)
9. urinalysis: specific gravity, acidity, al-
bumin, sugar, urobilinogen, sediment.
RESULTS
The results of the various examinations are
shown on Table I.
* We are indebted to Upjohn Company for
supplying Cortef ointment for this investigation.
Very few complications were noted clinically.
None of the few "side effects" were attributable
with any degree of certainty to the topical
application of hydrocortisonc.
Two patients developed pustular eruptions
and crusting, apparently as a result of secondary
infection in skin areas affected by severe excori-
ations from scratching. Local and systemic ad-
ministration of antibiotics without any inter-
ruption of the topical hydrocortisone applications
was promptly followed by clearance of the in-
fectious process.
A girl, 15 years of age, developed mild hyper-
trichosis on her face and arms, most likely
independently of the external treatment with
hydrocortisone.
increase in body weight by three or more
pounds was observed in 9 of the patients; seven
of these nine were children.
The blood pressure showed a decline in eight of
the patients, some risc in two, and pntctically
no change in nine of the patients. Moon facies,
edema, gastrointestinal symptoms and euphoria
were not observed in this series.
A comparison of the first laboratory results
obtained in a given subject with those obtained
subsequently (three or more months after the
initial examinations) shows the following:
Circulating eosinophile count (19 patients): A
decline was observed in four, no distinct change
or some rise in the remainder of the 19 patients.
Eosinophile differential count (18 patients): A
decrease occurred in seven, a doubtful decrease
in three, an increase in four, no change in two—
and questionable fluctuations in two of the 18
subjects examined.
Lymphocyte differential count (19 patients):
No change was noticeable in eight, an increase
in six though doubtful in three of these—and a
decline in five of the 19 subjects.
Monocyte differential count (19 patients): rihere
was a drop in nine, a questionable decline in two,
a rise in three, a questionable increase in one—
and no change in two of the 19 patients.
Urinary 17-ketosteroid excretion (16 patients):
A distinct increase was observed in five, a de-
crease in one, and no distinct change in the
remaining ten individuals under test. Blood
glucose (16 patients), serum sodium (13 patients),
serum chlorides (13 patients), serum calcium (13
patients), urinolysis (16 patients): "Normal".
Considering the range of variations usually
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TABLE I—Continued
encountered in one and the same subject, no
definite changes could be ascertained for any of
the patients examined.
DISCUSSION
The presented data strongly support previous
assumptions that external hydrocortisone therapy
is a safe modality regarding the risk of systemic
damage. In spite of the large amounts of hydro-
cortisone employed, none of the various labora-
tory findings (see table) is apt to evidence any
definite systemic change as a result of the appli-
cations. Percutaneous absorption of hydro-
cortisone which may have occurred, apparently
did not suffice to induce any of the ordinarily
detectable systemic effects to a significant de-
gree. On the other hand, it is conceivable that
none of the different laboratory tests performed
in this study is sensitive enough to warrant a
conclusive statement.
As is well known, the "circulating eosinophile
count," introduced as a test of adreno-cortieal
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function by Thorn et at. (16), shows a reduction
in response to intensified corticosteroid activity.
In agreement hcrewitb, Speirs (11) obtained
marked eosinopcnia following applications of
cortisone to the skin of adrenalectomized mice.
At first glance, the results listed on Table I
might suggest a trend in this direction, in view of
some drop in the eosinophile count in a number
of subjects. The dependability, however, of the
test results is known to be limited because of
unpredictable diurnal fluctuations of the count,
with a special tendency to decline following
stress situations.
In normal individuals Swanson et at. (15)
observed a high early morning count of the
circulating eosinophilcs which gradually falls
until midday; a slight rise occurs thereafter,
subsequently a fall again in the early aftemoon—
and another rise toward evening. Before noon
time these natural fluctuations may show a
reduction by as much as 50 per cent of the early
morning count, while the reduction usually
amounts to less tbau 40 per cent thereof in the
afternoon.
Considering the magnitude of these normal
variations it would hardly be justified to attribute
any importance to the changes in the count
noted in the present study, even though the
results of all the tests listed on Table I were
obtained around the same time of the day,
namely between 10:30 to 11:00 AM.
Whereas a transitory reduction in the number
of lymphocytes had been reported following
adrenal cortical stimulation by ACTH, no
definite trend is apparent in the lymphocyte
counts of this study.
The monocytc counts listed arc of some in-
terest, as these cells can be regarded as rcticulo-
endothelial elements sensu strictiori and a
reduction in number could possibly be a systemic
corticostcroid effect. Actually, six out of the 10
patients show a distinct reduction. Further
investigations arc necessary to appraise the
significance of this finding.
As is well known, hydrocortisonc depresses
adreno-corticotropin production, thus effecting a
reduction of adrenal androgens. It is, therefore,
noteworthy that in the present assays urinary
17-ketosteroid excretion has in no instance been
of higher magnitude, despite the massive doses
of hydrocortisone employed. Evidently, no
major amount had entered the system.
In agreement with the fact that sodium and
chloride retention thus far was not reported to
result from any external corticosteroid applica-
tion other than from the application of 9 alpha
fluorohydrocortisone (2, 4, 7), none of the pa-
tients subjected to the present examinations
have shown a "water-salt" imbalance.
It is noteworthy furthermore that neither
hyperglycemia nor glycosuria ever occurred
during this investigation. Systemic administra-
tion of hydrocortisone is known to promote the
conversion of protein into carbohydrate by
transformation of amino acid radicals to pyruvic
acid and glucose.
In a series of patients with various dermatologic
disorders treated locally with hydrocortisone
acetate ointment in some of the diseased areas,
Sulzbcrger, Witten and Smith (13) noted im-
provement in other untreated areas. The question
arose of a possible systemic effect caused by
absorption. During the present study the fol-
lowing experiment was performed in ten patients:
one arm affected by atopic dermatitis was
protected with a loose bandage for a period of
one to two weeks, while the other affected areas
were treated externally with hydrocortisonc
ointment. Five of these patients showed dis-
tinct improvement in the protected area similar
to the improvement observed in the treated
areas. Three other patients also showed some
improvement in the protected regions, but to a
definitely lesser degree than in the treated areas.
In two of the patients no improvement was
noticeable in the protected site. It appears
quite possible that the improvement observed
in the untreated areas was due to simple pro-
tection from trauma.
As a control, with regard to the validity of
the methods of assaying and appraising here
employed, two of our patients—not having
exhibited any manifestation of systemic effects
upon prolonged external hydrocortisonc therapy
—were given prednisolonc by mouth. One of
these two, upon receiving 761 mg. of prcdnisolone
over a period of eight weeks, showed "moon
facics" and weight gain (9 lbs.); and the circu-
lating cosinophilc count dropped from 566.1
to 66.6. The second patient, after receiving 760
mg. of prcdnisolonc over a period of seven
weeks, likewise responded with the features of
moon facics, weight gain (5 lbs.)—and a drop
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of the circulating eosinophilc count from 865.8
to 110.
SUMMARY
1. The present investigation was conducted
to determine whether or not undesirable sys-
temic effects may result from prolonged ex-
ternal application of large amounts of hydro-
cortisone to wide areas of damaged skin.
2. Nineteen patients were selected of which 10
were females and 9 males. Their ages ranged
from 5 to 60 years.
3. The amount of hydrocortisone applied per
subject ranged from 8,750 to 95,000 mg.
4. The duration of treatment was from three
to twenty months.
5. Clinical follow-up revealed no side effects
which could be attributed to the hydroeortisone
applications.
6. Laboratory assays (performed at inter-
vals), including circulating eosinophile counts,
white blood cell differentiation, urinary 17-
ketosteroid analyses, as well as quantitative
assays of blood glucose and serum electrolytes
did not show any distinct changes.
7. The results of this investigation strongly
suggest that external hydrocortisone treatment
does not produce any major systemic effects
following the use of large amounts over pro-
longed periods of time.
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